医药行业周报：强生Spravato获FDA批准，用于治疗TRD

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [6]. Core Insights - Johnson & Johnson's Spravato has received FDA approval for treating treatment-resistant depression (TRD) in adults, showing significant improvement in symptoms within 24 hours compared to placebo [2][6]. - The pharmaceutical sector experienced a slight decline of -0.15% on January 23, 2025, underperforming the CSI 300 Index by 0.33 percentage points, ranking 19th among 31 sub-industries [1]. - Notable performers within the sector included medical equipment (+0.87%), offline pharmacies (+0.63%), and blood products (+0.50%), while medical research outsourcing (-0.27%), medical consumables (-0.17%), and in vitro diagnostics (-0.08%) lagged behind [1]. Company Summaries - Qianhong Pharmaceutical (002550) forecasts a net profit of 320-380 million yuan for 2024, representing a year-on-year growth of 75.96%-108.95% [2]. - Tuobo Biotechnology (688767) anticipates a net profit of 170 million yuan for 2024, with a year-on-year increase of 59.47% [2]. - Pianzihuang (600436) expects 2024 revenue of 10.769 billion yuan, a 7.06% increase, and a net profit of 2.974 billion yuan, up 6.32% year-on-year [3].